Hsa-miR-330-5p Aggravates Thyroid Carcinoma via Targeting FOXE1

Yuxia Wang; Zhaozhe Liu; Xiangning Ren; Nan Sun; Qiuhua Li; Che Bian

doi:10.1155/2021/1070365

Hsa-miR-330-5p Aggravates Thyroid Carcinoma via Targeting FOXE1

J Oncol. 2021 Jul 2:2021:1070365. doi: 10.1155/2021/1070365. eCollection 2021.

Authors

Yuxia Wang¹, Zhaozhe Liu², Xiangning Ren¹, Nan Sun¹, Qiuhua Li³, Che Bian¹

Affiliations

¹ Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning, China.
² Oncology Department, General Hospital of Northern Theater Command, Shenyang 110014, Liaoning, China.
³ Oncology Department, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110034, Liaoning, China.

Abstract

Background: Thyroid carcinoma (TC) is one of the frequent endocrine malignancies, and growing evidence suggests that aberrant microRNA (miRNA) expression contributes to TC development and progression. Nevertheless, the function of miR-330-5p in the progression of TC remains unknown.

Methods: The expression levels of miR-330-5 in patients with thyroid carcinoma and healthy controls were detected, and their potential diagnostic and prognostic values were analyzed.

Results: In this study, we firstly found that miR-330-5p expression was markedly upregulated in TC tissue and cell lines. Functionally, the downregulation of miR-330-5p suppressed TC cell proliferation, migration, and invasion. Further studies revealed that miR-330-5p negatively regulated the expression of forkhead box E1 (FOXE1). More importantly, the results of rescue experiments suggested that FOXE1 overexpression reduced the positive effects of miR-330-5p overexpression in TPC-1 and K-1 cells.

Conclusions: This work revealed that miR-330-5p facilitated the TC progression through targeting FOXE1, which may offer novel therapeutic options for TC.